RADNOSTIX INC

INIS
About the company

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally. It operates through five segments: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products.

Country: United StatesPrice: $0.05Market Cap: $26.5M

Investment snapshot

0%positive consensus
Scored 1d ago

Positive

0

BUY / PASS

Neutral / negative

1 / 15

NEUTRAL / FAIL

Median fair value

—

No comparable estimates

Models with upside

0 / 17

Positive margin of safety

Key risk

No clean pass — all 13 investors flag at least one valuation criterion

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILFAIL · Rank #2167 (Top 70%)FAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Annual history · FY 2025

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30 · TTM ended 2026-06-30 vs 2025-06-30 · TTM ended 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-31

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-06-30 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Qualitative assessment

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Market data at 2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-31

Score computed: 2026-11-14

TTM ended 2026-06-30 · Balance sheet at 2026-06-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-06-30

Latest source filing: 2026-08-12

Score computed: 2026-11-14

TTM ended 2026-06-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-08-12

Score computed: 2026-11-14

Where It Passes

    Where It Falls Short

    • Valuation0% pass✓ 1✗ 27▾

      No clean pass — all 13 investors flag at least one valuation criterion

      Price / 3-yr avg EPS
      ✗Graham<= 15x
      Price-to-Book Ratio7.2x
      ✗Graham<= 1.5x
      P/E x P/B
      ✗Graham<= 22.5
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      EBIT / Enterprise Value-3.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-3.8%, ROC=-36.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Price / EPS
      ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
      Price / (CFO / Shares)42.6x
      ✗Dreman< 8x
      Price / Book Value per Share7.2x
      ✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)
      Valuation ReasonablenessOE Yield=-3.9%
      ✗MungerP/E < 25 or Owner Earnings Yield > 5%
      P/E or FCF YieldFCF Yield=0.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      P/B or P/E vs. Historical AverageP/B=7.2x
      ✗MarksP/E < 15 or P/B < 2.0
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Price / FCF per Share307.1x
      ✗Ackman<= 25
      Price vs. Trailing Low125% of trailing low ($0.04)
      ✗Templeton<= 120% of trailing low (certified split-adjusted live window)
      Net income / market capitalization-10.83%; #4214/6340 (top 66.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Positive book equity / market capitalization+0.0715; #4891/6449 (top 75.8%)
      ✗AsnessTop 30% of eligible cross-section
      Price / Diluted EPS
      ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
      (EPS CAGR % + Dividend Yield %) / P/E
      ✗Neff> 0.7 (Neff's published traditional edge)
      Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
      ✗SchlossP/TBV <= 1.00x (app cutoff)
      Book Value per Share Change+417.2%
      ✓SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
      Revenue / market capitalization+0.4243; #2847/5247 (top 54.3%)
      ✗OshaughnessyTop 10% of eligible cross-section
      (Operating cash flow - capex) / market capitalization-3.50%; #2863/4519 (top 63.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
      Trailing six-month price return through the evaluation date-44.44%; #4967/6202 (top 80.1%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Growth0% pass✓ 2✗ 11▾

      No clean pass — all 8 investors flag at least one growth criterion

      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      Inventory Growth vs Revenue GrowthInv: -3.9% vs Rev: -23.7%
      ✗LynchInventory growth < Revenue growth
      EPS Growth Direction$-0.02 (2010) -> $0.00 (2025)
      ✗DremanPositive over recent years
      EPS CAGR
      ✗Dreman> 5% annualized
      Positive Net Income Frequency3/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      3yr Median Revenue Growth9.7%
      ✓Ackman>= 5%
      Positive EPS Growth Frequency0/5 years with positive EPS growth
      ✗AckmanPositive EPS growth in >= 3 of last 5 years
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Revenue growth vs. gross and operating margin trendgross margin 60.2% -> 58.9%, operating margin -6.3% -> -7.3%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      5-year Revenue CAGR6.9%
      ✗SleepCAGR > 7%
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
    • Efficiency0% pass✗ 11▾

      All 8 investors flag INIS's efficiency

      Current Ratio0.84
      ✗Graham>= 2.0
      ROIC (3-5 yr avg)-28.6%
      ✗Buffett> 10%
      ROIC - WACC-38.6%
      ✗BuffettPositive (WACC = 10%)
      EBIT / (NWC + Net Fixed Assets)-36.1%
      ✗Greenblatt> 25%
      Current Ratio Change YoY1.50 -> 1.16
      ✗PiotroskiIncreased YoY
      Revenue / Total Assets Change YoY0.81x -> 0.73x
      ✗PiotroskiImproved YoY
      Current Assets / Current Liabilities0.84
      ✗Dreman> 1.5
      Return on Invested Capital-121.1%
      ✗Munger> 15%
      ROIC (high and growing)FY2023: ROIC=-14.6%; FY2024: ROIC=0.1%; FY2025: ROIC=-19.6%
      ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
      Reinvestment Rate x ROICN/A (non-positive net income)
      ✗AkreReinvestment Rate * ROIC > 10%
      ROIC (5-year)0/5 years above 12% (latest -19.6%)
      ✗SleepROIC > 12% in a majority of years
    • Verdicts0% pass✗ 16▾

      Split decision: 15 FAIL · 1 NEUTRAL

      Overall verdict
      ✗GrahamFAIL (0/9)✗BuffettFAIL (1/9)✗LynchFAIL (1/7)✗GreenblattRank #2167✗PiotroskiFAIL (F-Score 3)✗DremanFAIL (1/11)✗MungerFAIL (1/4)✗PabraiFAIL (0/3)✗AkreFAIL (2/6)✗MarksFAIL (0/5)✗AckmanFAIL (3/9)✗TempletonFAIL (2/8)✗SleepFAIL (2/6)✗AsnessFAIL (Rank #1705/2370 (Top 71.9%))✗NeffFAIL (1/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)
    • Profitability6% pass✓ 3✗ 32▾

      15 of 16 flag INIS's profitability — Graham, Buffett, Lynch +12 more

      Positive EPS (10 years)1/19 years positive
      ✗GrahamPositive EPS every year for 10 years
      EPS Growth (3-yr avg, 10-yr window)
      ✗Graham>= 33% growth
      Net Income Positive (10+ years)3/19 years positive
      ✗BuffettPositive every year for 10+ years
      ROE (up to 5-year arithmetic mean)-14.4%
      ✗Buffett> 15% arithmetic mean (app rule)
      Operating Margin (10-yr trend)-7.3% (latest)
      ✓BuffettStable or rising over 10 years
      Free Cash Flow Proxy$-1.0M
      ✗BuffettPositive and growing
      Earnings Variance (10-yr CoV)N/A (negative mean EPS)
      ✗BuffettCoV < 0.3
      Retained Earnings Effectiveness
      ✗Buffett$1 retained -> > $1 market value created
      Basic earnings-growth PEG (dividends excluded)
      ✗Lynch< 1.0 (ideally < 0.5)
      3-5 Year EPS CAGR
      ✗Lynch15-30% (Fast Grower); > 0% to pass
      ROE-151.4%
      ✗Lynch> 15%
      EBIT / Enterprise Value-3.8%
      ✗Greenblatt> 10%
      Earnings Yield + ROC AssessmentEY=-3.8%, ROC=-36.1%
      ✗GreenblattBoth EY > 10% and ROC > 25%
      Net Income / Total Assets-5.09%
      ✗PiotroskiROA > 0
      ROA Change YoY0.05% -> -5.09% (delta: -5.14%)
      ✗PiotroskiCurrent ROA > Prior ROA
      (CFO / Total Assets) vs ROACFO/Assets=3.48%, ROA=-5.09%
      ✓PiotroskiCFO/Assets > ROA
      Gross Margin Change YoY62.2% -> 58.9%
      ✗PiotroskiImproved YoY
      Pre-Tax Income / Revenue
      ✗Dreman>= 8%
      Net Income / Shareholders' Equity-151.4%
      ✗Dreman> 12%
      Margin of SafetyP/B=7.2x
      ✗PabraiP/B < 1.5 or P/E < 15
      Return on Equity-15.3% (3-yr avg)
      ✗AkreROE > 20% (3-year avg)
      Discount to Intrinsic ValueN/A (negative normalized EPS)
      ✗Marks>= 20% below intrinsic value
      Positive Net Income Frequency3/16 years positive
      ✗MarksPositive net income in >= 7 of last 10 years
      Operating Income / Revenue-25.8%
      ✗Ackman>= 15%
      Net Income / Shareholders Equity-151.4%
      ✗Ackman>= 15%
      5-Year EPS CAGR
      ✗Templeton> 0% (5-year EPS CAGR)
      Operating Margin Trend-6.3% (2023) -> -7.3% (2025)
      ✗TempletonNon-negative operating-margin trend over 3 years
      Revenue growth vs. gross and operating margin trendgross margin 60.2% -> 58.9%, operating margin -6.3% -> -7.3%
      ✓SleepRevenue rising; gross margin flat or falling; operating margin holding
      Net income / market capitalization-10.83%; #4214/6340 (top 66.5%)
      ✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-section
      Gross profit / total assets+36.28%; #1117/3702 (top 30.2%)
      ✗AsnessTop 30% of eligible cross-section
      Net income / positive book equity-151.39%; #4782/5226 (top 91.5%)
      ✗AsnessTop 30% of eligible cross-section
      Negative 5-year standard deviation of ROA-0.0310; #1953/5884 (top 33.2%)
      ✗AsnessTop 30% of eligible cross-section
      3-5 Year Diluted EPS CAGR
      ✗Neff7%-20% annualized
      Positive Diluted-EPS Years1/9 years positive
      ✗Schloss>= 70% positive over 5-10 observed years (app rule)
    • Cash Flow10% pass✓ 2✗ 10▾

      9 of 10 flag INIS's cash flow — Buffett, Lynch, Dreman +6 more

      Free Cash Flow Proxy$-1.0M
      ✗BuffettPositive and growing
      FCF Positive and Growing$-0.9M
      ✗LynchPositive and growing
      Operating Cash Flow$0.6M
      ✓PiotroskiCFO > 0
      (CFO / Total Assets) vs ROACFO/Assets=3.48%, ROA=-5.09%
      ✓PiotroskiCFO/Assets > ROA
      Price / (CFO / Shares)42.6x
      ✗Dreman< 8x
      P/E or FCF YieldFCF Yield=0.3%
      ✗PabraiP/E < 15 or FCF Yield > 10%
      FCF Positive6/14 years FCF positive
      ✗MarksPositive FCF in majority of recent years
      (OCF - CapEx) / Market Cap-3.5%
      ✗Ackman>= 4%
      Price / FCF per Share307.1x
      ✗Ackman<= 25
      Positive Operating Cash Flow frequency8/18 years positive
      ✗SleepPositive OCF in >= 70% of available years
      Operating Cash Flow - Capital Expenditures$-0.9M
      ✗Neff> $0 (app proxy for a strong fundamental case)
      (Operating cash flow - capex) / market capitalization-3.50%; #2863/4519 (top 63.4%)
      ✗OshaughnessyTop 10% of eligible cross-section
    • Debt & Leverage50% pass✓ 9✗ 6▾

      6 of 12 pass — Graham, Buffett, Lynch +3 more object

      LT Debt vs Net Current AssetsLT Debt $1.9M vs NCA $0.7M
      ✗GrahamLT Debt <= Net Current Assets
      Debt/Equity & Interest CoverageD/E: 0.00, IC: -8.5x
      ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
      Total Debt / Equity0
      ✓Lynch< 0.33
      Cash - Long-term Debt$-0.2M
      ✗LynchPositive preferred
      LT Debt / Total Assets Change12.86% -> 10.83%
      ✓PiotroskiDecreased YoY
      Current Assets / Current Liabilities0.84
      ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
      Total Debt / Shareholders' Equity0
      ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
      Debt Levels0
      ✓MungerDebt/Equity < 0.5✓AkreDebt/Equity < 0.3
      Interest Coverage & Debt/EBITDAIC=-8.5x, D/EBITDA=0.0x (no debt)
      ✗MarksInterest Coverage > 3x; Debt/EBITDA < 4x
      Total Debt / Shareholders Equity0
      ✓Ackman<= 1.0
      Negative debt-to-equity (higher means less debt)-0.0000; #1/4210 (top 0.0%)
      ✓AsnessTop 30% of eligible cross-section

    Business & financials

    Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

    Company Profile

    Industry: Measuring and Control Equipment
    SIC Sector: Measuring & Medical Instruments
    Size: Micro Cap($26.5M)
    Revenue: $13.1M-6.0% YoY
    Net Income: $-908002.00-10690.2% YoY

    Financial Snapshot

    Operating Margin-7.3%
    Return on Equity-24.6%
    Debt / Equity0.04
    Current Ratio1.16
    EPS (Diluted)$0.00
    Shares Retired−0.9% / −1.6% 2y

    Shareholder Return

    Fiscal 2025

    Issued 0.9% of shares last year, 1.6% issued over two.

    Buybacks
    —
    Dividends
    —

    Company Financials

    Latest TTM and quarters alongside annual years

    TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

    The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

    MetricTTM · 2026-06-30

    2025-07-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex, revenue, net income, operating income, gross profit, ebit, interest expense, depreciation amortization.

    Q2 FY 2026

    2026-04-01 – 2026-06-30

    Sources · derived quarter values

    Derived from cumulative filings: operating cash flow, capex.

    Q1 FY 2026

    2026-01-01 – 2026-03-31

    Sources
    FY 2025
    Sources
    • 10-K · 2026-03-31
    FY 2024
    Sources
    • 10-K · 2025-03-04
    FY 2023
    Sources
    • 10-K · 2024-03-29
    FY 2022
    Sources
    • 10-K · 2023-04-06
    FY 2021
    Sources
    • 10-K · 2022-03-31
    Market Cap$26.5Mcurrent----$37.0Mest.$20.9Mest.$26.0Mest.$20.6Mest.$45.3Mest.
    Revenue$11.2M↓24%$2.7M↓27%$2.4M↓27%$13.1M↓6%$13.9M↑13%$12.3M↑10%$11.2M↑16%$9.7M
    Operating Income-$2.9M↓1245%-$834.2K↓519%-$1.3M↓1915%-$956.2K↓13956%$6.9K↑101%-$776.3K↑35%-$1.2M↓77%-$680.8K
    Net Income-$2.9M↓2437%-$882.0K↓449%-$1.3M↓1096%-$908.0K↓10690%$8.6K↑101%-$869.0K↓387%$303.2K↑134%-$902.3K
    EPS (Diluted)--$0.00$0.00$0.00$0.00$0.00$0.00$0.00
    Gross Margin53.8%↓11%50.9%↓13%48.4%↓23%58.9%↓5%62.2%↑3%60.2%↑7%56.3%↓5%59.4%
    Operating Margin-25.8%↓1601%-31.2%↓746%-55.1%↓2643%-7.3%↓14835%0.0%↑101%-6.3%↑41%-10.8%↓53%-7.0%
    ROE-151.4%↓5368%——-24.6%↓12566%0.2%↑101%-21.5%↓408%7.0%↑121%-33.0%
    Total Debt$0$0$0$162.7K↓47%$308.4K↑98%$155.7K↑170%$57.8K↓83%$347.8K
    Shareholders' Equity$1.9M↓56%$1.9M↓56%$2.6M↓39%$3.7M↓15%$4.3M↑8%$4.0M↓7%$4.3M↑59%$2.7M
    Current Ratio0.84↓43%0.84↓43%0.88↓11%1.16↓22%1.50↓15%1.76↑8%1.63↑147%0.66
    Debt / Equity0.000.000.000.04↓38%0.07↑84%0.04↑190%0.01↓90%0.13
    Operating Cash Flow-$376.3K↓157%-$613.6K↓294%-$72.4K↓1315%$620.2K↓3%$638.8K↑10%$582.6K↑139%-$1.5M↓825%-$161.9K
    Free Cash Flow-$925.2K↓2469%-$613.6K↓341%-$277.6K↓107%$86.0K↑204%-$82.4K↓119%$433.5K↑127%-$1.6M↓340%-$367.4K

    Score history

    Historical Score Timeline

    Industry peers

    Industry Peers

    Similar companies in Measuring and Control Equipment

    INIS vs Peers — Financial Grading

    Revenue$13.1MBottom 25%
    Net Income$-908002.00Bottom 25%
    ROE-24.6%Bottom 25%
    D/E0.04Top 25%
    Op. Margin-7.3%Bottom 25%
    Curr. Ratio1.16Bottom 25%
    CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
    THERMO FISHER SCIENTIFIC INC.TMO$259.4B$700.22$44.6B$6.7B12.6%0.7417.4%1.893/93/93/71/3F-Score 57/11
    DANAHER CORP /DE/DHR$163.9B$233.02$24.6B$3.6B6.9%0.3519.1%1.873/94/92/71/3F-Score 54/11
    WATERS CORP /DE/WAT$90.5B$460.25$3.2B$642.6M25.1%0.5525.4%1.731/94/91/70/3F-Score 45/11
    AGILENT TECHNOLOGIES, INC.A$49.0B$173.96$6.9B$1.3B19.3%0.4521.3%1.962/95/93/71/3F-Score 55/11
    ROPER TECHNOLOGIES INCROP$47.5B$479.98$7.9B$1.5B7.7%0.4728.3%0.522/93/93/70/3F-Score 64/11
    COHERENT CORP.COHR$43.0B$218.15$5.8B$49.4M0.9%0.691.6%2.193/91/90/70/3F-Score 44/11
    TERADYNE, INCTER$39.0B$249.55$3.2B$554.0M19.8%0.0720.4%1.752/96/94/71/3F-Score 66/11
    ILLUMINA, INC.ILMN$31.3B$207.01$4.3B$850.0M31.2%0.7318.6%2.082/91/93/71/3F-Score 85/11